Latest news with #healthcareAI
Associated Press
08-07-2025
- Health
- Associated Press
Clinician-Powered AI Solutions Set a New Standard: Black Book Survey Reveals Six Vendors Earning Near-Perfect User Scores
Clinician Co-Design Sets a New 2025 Bar for Healthcare AI TAMPA, FL / ACCESS Newswire / July 8, 2025 / While healthcare AI adoption is frequently hindered by poor design, weak integration, and limited clinician involvement, six standout vendors have defied these industry-wide trends, according to a new Black Book Research survey. Conducted among 448 clinicians in Q2 2025, the study highlights how direct clinician involvement in AI design and development has delivered measurable, immediate clinical impact, with nearly 100% clinician satisfaction. Qualitative KPIs to Measure Clinician Input and AI Usability The following eight qualitative key performance indicators (KPIs) have been exclusively designed to measure how clinicians' insights directly shape the usability and effectiveness of AI solutions in healthcare: The following vendors ranked highest among over 200 evaluated, with near-perfect cumulative scores on these KPIs: Epic Systems (EHR & Clinical AI) - 9.97/10 Epic Systems demonstrates exceptional clinician-powered design through its 'Physician Builder' program, embedding frontline clinicians into every product stage. Clinicians rate Epic highly for Workflow Fit, User Satisfaction, Adoption & Sustained Use, and Time Savings, noting dramatically reduced documentation burdens and enhanced patient interactions. Signal 1 (Predictive Analytics & Clinical Decision Support) - 9.95/10 Signal 1 excels in predictive analytics and clinical decision support by deeply involving hospital-based clinical teams in solution development. Clinicians praised Signal 1's Clinical Impact, User Satisfaction, Transparency, and Workflow Fit, highlighting its seamless integration into care routines and meaningful impact on patient outcomes. Aidoc (Imaging AI & Radiology) - 9.93/10 Aidoc distinguishes itself through continuous development alongside practicing radiologists, ensuring optimal workflow alignment and usability. With exceptional ratings for Clinical Impact, Workflow Fit, and User Satisfaction, radiologists endorse Aidoc for providing precise, actionable diagnostic insights seamlessly integrated into daily practices. Suki AI (Digital Clinical Assistant) - 9.91/10 Suki AI's voice-enabled clinical assistant platform, designed through ongoing clinician collaboration, achieves high scores in User Satisfaction, Workflow Fit, and Feedback Loop Responsiveness. Clinicians highlight Suki's intuitive usability, considerable time savings, and consistent responsiveness to real-world user feedback. Notable (Workflow Automation & Ambient Documentation AI) - 9.90/10 Notable's clinician-first approach actively incorporates frontline user feedback, resulting in high scores for Workflow Fit, Feedback Loop Responsiveness, Transparency & Trust, and Adoption & Sustained Use. Clinicians commend Notable's seamless integration and significant reduction in administrative workload. (Imaging & Acute Care Coordination AI) - 9.90/10 collaborates directly with neurologists, radiologists, and emergency physicians, delivering immediate and measurable clinical outcomes, notably rapid stroke interventions. Clinicians awarded top marks in Clinical Impact, Workflow Fit, Time Savings, and Transparency & Trust, emphasizing the solution's actionable and timely insights. __________ Clinician-Centric Design Drives True AI Success 'Healthcare AI's greatest successes don't arise from technical brilliance alone, they are rooted in deeply embedding clinicians within the design and deployment process,' notes Doug Brown, Black Book's Founder. 'These six standout vendors represent a new breed of AI innovation, demonstrating what's possible when frontline clinical expertise guides technology. In a healthcare environment often overwhelmed by disconnected, frustrating technology, these companies offer a compelling vision of what clinician-powered AI can truly achieve immediate usability, rapid adoption, measurable clinical outcomes, and meaningful clinician satisfaction.' About Black Book Research Black Book™ is the healthcare industry's leading independent research and survey organization, trusted by healthcare providers, payers, and investors. Black Book maintains a vast database comprising over 3.3 million responses from healthcare IT users, clinicians, executives, and operational users across more than 10,000 healthcare programs, software solutions, managed services, outsourcing initiatives, consulting firms, start-ups, and capital equipment suppliers globally including input from 65 countries. Black Book's rigorous research methodology provides deep, unbiased insights into healthcare technology and service performance, empowering informed strategic decision-making across the healthcare industry. Media Contact: [email protected] Contact InformationPress Office 8008637590 SOURCE: Black Book Research press release
Yahoo
03-07-2025
- Business
- Yahoo
Guggenheim Raises GeneDx (WGS) Price Target, Maintaining a Buy Rating
GeneDx Holdings Corp (NASDAQ:WGS) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Guggenheim analyst Subbu Nambi has raised the price target for GeneDx Holdings Corp (NASDAQ:WGS) from $88.00 to $115.00, reinforcing a bullish stance on the company's long-term trajectory. The 'Buy' rating remains unchanged, signaling confidence in GeneDx's market position and its potential to capture a growing share of the precision medicine space. A modern office space where the team is engaging in business development and management services. GeneDx, known for its deep expertise in rare disease genomics and next-generation sequencing, is emerging as a leader in healthcare innovation. The company blends advanced bioinformatics with clinical expertise to help physicians diagnose complex, genetically driven conditions more efficiently. Its platform leverages massive datasets and machine learning algorithms to interpret whole-genome and exome sequencing, placing it squarely in the center of the healthcare AI movement. The price target hike reflects Guggenheim's view that GeneDx is well-positioned to benefit from the increasing demand for personalized medicine and the broader integration of data-driven tools in clinical care. As health systems and biopharma partners seek faster, more accurate diagnostic solutions, GeneDx's technology and scalable infrastructure make it a critical player in the shift toward AI-enabled healthcare. With momentum building across both clinical and commercial channels, the company appears to be gaining traction at a pivotal time for genomic medicine. The revised valuation underscores growing investor recognition of GeneDx's role in transforming how rare and complex diseases are diagnosed and managed. While we acknowledge the potential of WGS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than WGS and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio
Yahoo
03-07-2025
- Business
- Yahoo
Morgan Stanley Raises iRhythm (IRTC) Price Target, Maintains Overweight Rating
iRhythm Technologies, Inc. (NASDAQ:IRTC) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Morgan Stanley has raised its price target on iRhythm Technologies, Inc. (NASDAQ:IRTC) to $160 from $130, while maintaining an 'Overweight' rating, citing strong early indicators for the company's second-quarter performance. In a recent note to investors, the firm pointed to a surge in MyZio app downloads, which totaled 171,169 in Q2—up 74% year-over-year and 36% compared to the first quarter. The increase suggests iRhythm may outperform Street estimates, as most of the Zio patches generating revenue for the quarter have already been prescribed and tied to active monitoring. A patient being monitored with a portable ECG device, showing the effectiveness of the company's products. Morgan Stanley highlighted that the strong app adoption signals growing patient engagement and broader acceptance of digital cardiac care, which bodes well for both short- and long-term growth. With scalable infrastructure and a rising volume of clinical data feeding its algorithms, iRhythm is not only improving detection but also redefining remote patient monitoring. As healthcare shifts toward personalized, tech-driven models, iRhythm's innovation and execution place it among the leaders in digital diagnostics. Morgan Stanley views the company as a compelling investment amid increasing demand for smart, connected health solutions. iRhythm Technologies, Inc. (NASDAQ:IRTC) develops and markets the Zio platform, a patch-based cardiac monitoring solution that leverages advanced analytics and machine learning to detect arrhythmias with clinical-grade accuracy. The company's AI-enabled technology analyzes millions of heartbeats in real time, helping physicians diagnose conditions like atrial fibrillation more effectively than traditional methods. While we acknowledge the potential of IRTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IRTC and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio
Yahoo
03-07-2025
- Business
- Yahoo
Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505
Schrödinger, Inc. (NASDAQ:SDGR) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Schrödinger, Inc. (NASDAQ:SDGR) announced that its investigational drug SGR-1505 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of adults with Waldenström macroglobulinemia who have not responded to at least two prior therapies, including a Bruton's tyrosine kinase (BTK) inhibitor. The designation is designed to expedite the development and review of drugs that address serious or life-threatening conditions with unmet medical need. A biopharmaceutical executive discussing plans with a government laboratory. SGR-1505 is a selective MALT1 inhibitor currently in clinical development. Waldenström macroglobulinemia is a rare type of non-Hodgkin lymphoma, and treatment-resistant forms present significant challenges for patients and clinicians. Schrödinger's approach to drug discovery gives it a unique advantage in targeting such difficult diseases. The company is best known for its computational platform that integrates physics-based modeling and advanced algorithms to design novel compounds with greater precision and efficiency. This model-driven strategy makes Schrödinger one of the few healthcare companies at the forefront of computational drug discovery—a field that blends molecular science with cutting-edge software to identify and optimize potential therapies faster than traditional methods. With the FDA's Fast Track status, SGR-1505 may benefit from more frequent interaction with the agency and potential eligibility for accelerated approval, positioning Schrödinger to advance an important treatment option while reinforcing its growing role as a technology-driven innovator in the pharmaceutical sector. While we acknowledge the potential of SDGR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SDGR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-07-2025
- Business
- Yahoo
Guggenheim Raises Tempus AI (TEM) Price Target, Maintaining Buy Rating
Tempus AI, Inc. (NASDAQ:TEM) is one of the top 10 healthcare AI stocks to buy according to hedge funds. On June 30, 2025, Guggenheim analyst Subbu Nambi reaffirmed a 'Buy' rating on Tempus AI, Inc. (NASDAQ:TEM), while raising the firm's price target from $65.00 to $75.00. The revised target reflects growing confidence in Tempus' expanding role in transforming clinical care through precision medicine and data-driven insights. A technician in a lab coat working on a specialized multi-axis coating system. Guggenheim's updated price target follows steady progress in Tempus' commercial partnerships and a growing footprint in both academic medicine and biopharmaceutical development. The analyst highlighted the company's ability to scale its platform across specialties, pointing to its integrated software, sequencing, and analytics solutions as core strengths in a rapidly evolving healthcare landscape. As demand for personalized and evidence-based care accelerates, Tempus AI, Inc. (NASDAQ:TEM) is well-positioned to play a central role in the shift toward smarter, more predictive medicine. Guggenheim's outlook underscores the firm's belief that Tempus' growth trajectory is both sustainable and strategically aligned with the future of healthcare delivery. Tempus AI operates at the intersection of technology and healthcare, using one of the largest structured clinical and molecular data libraries in the world to personalize treatment decisions. The company works with hospitals, research institutions, and pharmaceutical firms to integrate real-world evidence into patient care, particularly in oncology, cardiology, and infectious diseases. Tempus' proprietary platform uses machine learning and high-performance computing to uncover patterns in clinical and genomic data, enabling more accurate diagnoses and more effective therapies. While we acknowledge the potential of TEM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEM and that has 100x upside potential, check out our report about this cheapest AI NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
